Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Short-chain fatty acid production via microbial fermentation refers to the generation of small organic acids—primarily acetate (C2), propionate (C3), and butyrate (C4)—by anaerobic bacteria in the large intestine through the breakdown of indigestible polysaccharides such as dietary fiber. These metabolites are crucial for colonic health because they serve as energy sources for colonocytes and modulate various physiological processes including immune regulation, metabolic homeostasis, appetite control, inflammation modulation (notably in conditions like irritable bowel syndrome), and even neurodevelopment through effects on microglia. The quantity produced depends on diet composition and microbiota diversity. While essential for maintaining gastrointestinal integrity and systemic health benefits have been described—including roles in cardiometabolic regulation—the term does not refer to any single molecular entity suitable for direct pharmacologic targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Short-chain fatty acid production via microbial fermentation (SCFA production).